Quarterly report pursuant to Section 13 or 15(d)

Royalty and Commercial Payment Purchase Agreements - LadRx (Details)

v3.24.3
Royalty and Commercial Payment Purchase Agreements - LadRx (Details) - USD ($)
3 Months Ended 9 Months Ended
Jun. 03, 2024
Jan. 11, 2024
Jun. 21, 2023
Mar. 31, 2024
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Agreements              
Payments of consideration under RPAs, AAAs and CPPAs         $ 37,000,000 $ 14,650,000  
Contingent consideration under RPAs, AAAs and CPPAs         4,000,000   $ 7,000,000
Change in fair value of contingent consideration under RPAs, AAAs, and CPPAs           $ (75,000)  
LadRx | Assignment and Assumption Agreement and Royalty Purchase Agreement              
Agreements              
Amount of regulatory milestone payment removed $ 4,000,000.0            
Payments of consideration under RPAs, AAAs and CPPAs     $ 5,000,000.0        
Maximum regulatory and commercial sales milestone payments     6,000,000.0        
Maximum commercial sales milestone payments     1,000,000.0        
Contingent consideration, high-end of range         0    
Contingent consideration under RPAs, AAAs and CPPAs         1,000,000.0    
Acquisition of royalty and commercial payment receivables, Long-Term     6,000,000.0        
Short-term royalty and commercial payment receivables from milestone payment         2,200,000    
Short-term royalty and commercial payment receivables from royalty or commercial payment         0    
Allowance for credit losses         0   0
LadRx | Assignment and Assumption Agreement and Royalty Purchase Agreement | Regulatory milestones              
Agreements              
Payments of consideration under RPAs, AAAs and CPPAs   $ 1,000,000.0   $ 1,000,000.0 1,000,000.0    
Contingent consideration, high-end of range     5,000,000.0        
Contingent consideration under RPAs, AAAs and CPPAs $ 0   $ 1,000,000.0 $ 0 $ 0   $ 1,000,000.0